Press Releases Atea Pharmaceuticals, Inc.

Equities

AVIR

US04683R1068

Real-time Estimate Cboe BZX Other stock markets 12:29:03 2024-05-14 pm EDT			5-day change	1st Jan Change
3.985 ^USD	-1.36%		+1.02%	+30.49%

Mar. 27	Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients	CI
Feb. 28	Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024	May. 07	AQ
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024	Apr. 29	AQ
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients	Mar. 27	AQ
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Feb. 28	AQ
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024	Feb. 21	AQ
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19	Jan. 08	AQ
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 03	AQ
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023	Nov. 13	AQ
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 08	AQ
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences	Nov. 08	AQ
Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023	Nov. 02	AQ
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023	Nov. 01	AQ
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference	23-09-06	AQ
Atea Pharmaceuticals : Second Quarter 2023 Financial Results Conference Call Presentation	23-08-08	PU
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update	23-08-08	AQ
Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023	23-08-01	AQ
Atea Pharmaceuticals : Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year - Form 8-K	23-06-21	PU
ATEA PHARMACEUTICALS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	23-06-21	AQ
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination	23-06-15	AQ
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference	23-06-05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Atea Pharmaceuticals, Inc.

Equities

AVIR

US04683R1068

Press Releases

Filters